It was a pleasure to catch up with Prof. Detlef Schuppan (Mainz University Medical Center, Mainz, Germany) following his presentations at virtual UEG week to discuss the current unmet needs in the treatment of celiac disease and advances being made in its management.
His presentation entitled ‘ORAL INHIBITOR OF TISSUE TRANSGLUTAMINASE PREVENTS MUCOSAL DAMAGE IN CELIAC PATIENTS UNDERGOING GLUTEN CHALLENGE’ was given at UEG Week Virtual, 3-5 Oct 2021.
Questions
- What are the unmet needs in the management of patients with celiac disease? (0:15)
- How has our increased understanding of the pathogenesis of celiac disease guided the development of novel strategies? (1:43)
- What novel approaches are being investigated in clinical trials into the management of celiac disease? (2:58)
Disclosures: Prof. Detlef Schuppan has no personal financial interests in relation to the content of this video interview; however, discloses scientific-clinical activities with research support from Zedira, Falk Pharma, Topas Therapeutics, Calypso and DFG.
Support: Interview and filming supported by Touch Medical Media. Interview conducted by Gina Furnival.
Filmed in coverage of UEG Week Virtual, 3-5 Oct 2021.
